The Evolving Second-Line Treatment Landscape in HR+, HER2- Metastatic Breast Cancer
As part of its Case-Based Digest series, Oncology Nursing News spoke with experts about second-line treatment of HR-positive, HER2-negative metastatic breast cancer.
Bispecific Antibody Therapies in Multiple Myeloma
As part of the Community Case Forum series, key opinion leaders and participants discuss the use of bispecific antibodies the treatment of patients with multiple myeloma.
Second-Line Treatment for HR+, HER2- Metastatic Breast Cancer
In this Community Case Forum series, experts and participants discuss the evolving landscape of second-line treatment for patients with HR+, HER2- metastatic breast cancer.
CAR T-Cell Therapies for Multiple Myeloma
As part of its Community Case Forum series, key opinion leaders and participants discuss the use of CAR T-cell therapy for the treatment of patients with multiple myeloma.
Development of Immunotherapy for Advanced Endometrial Cancer
As part of its Community Case Forum series, key opinion leaders and participants discuss the development of immunotherapy for patients with advanced endometrial cancer.
NKT2152 Shows Promising Efficacy in Advanced Clear Cell Kidney Cancer
T-DXd Outranks Treatment of Physicians’ Choice in QOL for HR+/HER2-Low/Ultralow MBC
Nivolumab With or Without Ipilimumab Sustains 10-Year Survival Benefit in Advanced Melanoma
Breastfeeding Is OK During Endocrine Therapy Break for HR+ Breast Cancer